Metropolitan Life Insurance Company (MetLife)’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-415
| Closed | -$9.41K | – | 1132 |
|
|
2024
Q1 | $9.41K | Buy |
+415
| New | +$7.28K | ﹤0.01% | 2151 |
|
|
2023
Q4 | – | Sell |
-416
| Closed | -$8.36K | – | 2369 |
|
|
2023
Q3 | $8.36K | Hold |
416
| – | – | ﹤0.01% | 2288 |
|
|
2023
Q2 | $11.2K | Buy |
416
+131
| +46% | +$5.64K | ﹤0.01% | 2240 |
|
|
2023
Q1 | $16.6K | Sell |
285
-23
| -7% | -$1.14K | ﹤0.01% | 1978 |
|
|
2022
Q4 | $15.7K | Hold |
308
| – | – | ﹤0.01% | 2120 |
|
|
2022
Q3 | $25.2K | Buy |
308
+131
| +74% | +$9.79K | ﹤0.01% | 1900 |
|
|
2022
Q2 | $12K | Sell |
177
-144
| -45% | -$13.2K | ﹤0.01% | 2274 |
|
|
2022
Q1 | $35.5K | Sell |
321
-544
| -63% | -$67.8K | ﹤0.01% | 1787 |
|
|
2021
Q4 | $83.5K | Buy |
865
+96
| +12% | +$9.57K | ﹤0.01% | 2572 |
|
|
2021
Q3 | $67.1K | Sell |
769
-714
| -48% | -$74.1K | ﹤0.01% | 2714 |
|
|
2021
Q2 | $230K | Buy |
1,483
+192
| +15% | +$27.9K | ﹤0.01% | 2043 |
|
|
2021
Q1 | $204K | Sell |
1,291
-158
| -11% | -$33.3K | ﹤0.01% | 2009 |
|
|
2020
Q4 | $337K | Hold |
1,449
| – | – | 0.01% | 1615 |
|
|
2020
Q3 | $317K | Hold |
1,449
| – | – | 0.01% | 1507 |
|
|
2020
Q2 | $412K | Buy |
1,449
+232
| +19% | +$68.6K | 0.01% | 1359 |
|
|
2020
Q1 | $351K | Sell |
1,217
-153
| -11% | -$42.2K | 0.01% | 1262 |
|
|
2019
Q4 | $394K | Sell |
1,370
-51
| -4% | -$11.1K | 0.01% | 1477 |
|
|
2019
Q3 | $205K | Buy |
1,421
+1,111
| +358% | +$151K | ﹤0.01% | 1864 |
|
|
2019
Q2 | $27.8K | Buy |
+310
| New | +$24.9K | ﹤0.01% | 2562 |
|
|
2019
Q1 | – | Sell |
-1,085
| Closed | -$152K | – | 2564 |
|
|
2018
Q4 | $152K | Hold |
1,085
| – | – | ﹤0.01% | 1995 |
|
|
2018
Q3 | $277K | Hold |
1,085
| – | – | ﹤0.01% | 1777 |
|
|
2018
Q2 | $277K | Buy |
1,085
+304
| +39% | +$75.2K | ﹤0.01% | 1727 |
|
|
2018
Q1 | $157K | Buy |
781
+36
| +5% | +$7.18K | ﹤0.01% | 2045 |
|
|
2017
Q4 | $107K | Sell |
745
-716
| -49% | -$115K | ﹤0.01% | 2272 |
|
|
2017
Q3 | $241K | Hold |
1,461
| – | – | ﹤0.01% | 2171 |
|
|
2017
Q2 | $198K | Hold |
1,461
| – | – | ﹤0.01% | 2341 |
|
|
2017
Q1 | $281K | Hold |
1,461
| – | – | ﹤0.01% | 2052 |
|
|
2016
Q4 | $206K | Buy |
1,461
+164
| +13% | +$22.2K | ﹤0.01% | 2334 |
|
|
2016
Q3 | $189K | Sell |
1,297
-50
| -4% | -$6.01K | ﹤0.01% | 2370 |
|
|
2016
Q2 | $136K | Buy |
+1,347
| New | +$175K | ﹤0.01% | 2557 |
|
|
2016
Q1 | – | Sell |
-1,128
| Closed | -$224K | – | 2517 |
|
|
2015
Q4 | $224K | Hold |
1,128
| – | – | ﹤0.01% | 2177 |
|
|
2015
Q3 | $178K | Hold |
1,128
| – | – | ﹤0.01% | 2362 |
|
|
2015
Q2 | $460K | Buy |
+1,128
| New | +$488K | ﹤0.01% | 1806 |
|
|
2015
Q1 | – | Sell |
-653
| Closed | -$367K | – | 2330 |
|
|
2014
Q4 | $367K | Hold |
653
| – | – | ﹤0.01% | 1980 |
|
|
2014
Q3 | $342K | Hold |
653
| – | – | ﹤0.01% | 1979 |
|
|
2014
Q2 | $456K | Buy |
653
+230
| +54% | +$107K | ﹤0.01% | 1897 |
|
|
2014
Q1 | $196K | Sell |
423
-258
| -38% | -$131K | ﹤0.01% | 2469 |
|
|
2013
Q4 | $234K | Buy |
+681
| New | +$188K | ﹤0.01% | 2358 |
|
Other funds holding KPTI
PAI
EP
Metropolitan Life Insurance Company (MetLife)'s KPTI Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 415 shares — an estimated $9.41K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in KPTI in Q4 2013 and held it in 38 quarters. The position peaked at $460K in Q2 2015. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 415 Karyopharm Therapeutics shares in Q2 2024, an estimated $9.41K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 38 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Karyopharm Therapeutics position peaked at $460K in Q2 2015.
- 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.